Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Warrants (Tables)

Warrants (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

At September 30, 2016, the following warrants to purchase Common Stock were outstanding:

				Weighted			Weighted
				Average			Average
	Number of			Exercise			Remaining
	Awards			Price			Term in Years
Outstanding at December 31, 2015		1,983,673		$	9.18			5.32
Issued		871,000	¹		3.50	²		4.74
Forfeited		(1,937)			9.18			4.82
Outstanding at September 30, 2016		2,852,736		$	7.45			4.59

¹ Consists of 1,742,000 warrants to purchase 837,500 shares of Common Stock issued to the investor, and 33,500 shares issued to the Sales Agent, in connection with the Company’s registered direct offering on June 30, 2016.

² Warrant exercise price for a full share of Common Stock. Each warrant issued is for the purchase of one-half of a share of Common Stock.

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details